

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

DiFi

RRID:CVCL_6895

Type: Cell Line

Proper Citation

RRID:CVCL_6895

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6895

Proper Citation: RRID:CVCL_6895

Description: Cell line DiFi is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colorectal carcinoma

Defining Citation: [PMID:8385096](#), [PMID:20570890](#), [PMID:22270724](#), [PMID:22722830](#), [PMID:25623215](#), [PMID:25926053](#), [PMID:27397505](#), [PMID:28854368](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0002000000030). It was one of the sources for the STR profile of this entry., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DiFi

Synonyms: DIFI

Cross References: BTO:BTO_0005902, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:856, cancercellines:CVCL_6895, Cell_Model_Passport:SIDM00049, Cosmic:1479628, Cosmic:1519358, Cosmic:2841360, Cosmic-CLP:1789883, DepMap:ACH-002233, EGA:EGAS00001000978, GDSC:1789883, GEO:GSM1448175, GEO:GSM1669732, KCB:KCB 2014033YJ, PharmacDB:DIFI_291_2019, PRIDE:PXD005235, PRIDE:PXD030304,

PubChem_Cell_line:CVCL_6895, Wikidata:Q54831091

ID: CVCL_6895

Record Creation Time: 20220427T215818+0000

Record Last Update: 20260905T175230+0000

Ratings and Alerts

No rating or validation information has been found for DiFi.

No alerts have been found for DiFi.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. EMBO molecular medicine, 18(6), 2322.

Kim J, et al. (2024) Comparison of EV characterization by commercial high-sensitivity flow cytometers and a custom single-molecule flow cytometer. Journal of extracellular vesicles, 13(8), e12498.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine, 5(2), 101376.

Koganemaru S, et al. (2023) Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry. British journal of pharmacology, 180(6), 762.

Zhang Q, et al. (2023) Comprehensive isolation of extracellular vesicles and nanoparticles. Nature protocols, 18(5), 1462.

Rau A, et al. (2022) Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. Molecular cancer therapeutics, 21(5), 799.

Jeppesen DK, et al. (2019) Reassessment of Exosome Composition. Cell, 177(2), 428.

Smeets D, et al. (2018) Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature communications, 9(1), 4112.